Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- CRPC Drugs Xtandi, Zytiga Neck-and-Neck in Key Opinion Leader Poll
April 1, 2015
- New Stroke Guidelines to “Strongly Recommend” NOACs for NVAF
March 31, 2015
- Keytruda Demonstrates Superior OS, PFS to Yervoy in Advanced Melanoma in PIII Study: Merck
March 30, 2015
- Univ. of Tokyo to Provide Access to Comprehensive Database of Drug and Medical Device Seeds Starting in April
March 26, 2015
- Drug-Use Result Surveys Should Be Conducted in Elaborate Manner: Dr Narukawa
March 25, 2015
- Yervoy Extends Survival of Terminal Melanoma Patients, Same Might Hold True for Other Immunotherapies: Prof.
March 19, 2015
- Researcher Has High Hopes for Immunotherapies as Fourth Pillar of Cancer Treatment
March 17, 2015
- Large-Scale Genomic Screening Project Gets Underway to Make Gene Database of 4,500 Cancer Patients
March 12, 2015
- Urological Cancer Society to Be Inaugurated in October
March 12, 2015
- Interview on SGLT-2 Inhibitor Use (2): Prof. Watada Calls for Caution in Analyzing EPPV Data
March 9, 2015
- Interview on SGLT-2 Inhibitor Use (1): Prof. Ueki Says Flat Sales Reflect Cautious Prescribing by Physicians
March 6, 2015
- Astellas, Nagasaki Univ. Extend Joint Research Deal for Dengue Fever by 1 Year
March 3, 2015
- No Problems Found with Integrity of CASE-J Data Analyses: Kyoto Univ.
March 2, 2015
- Govt-Backed Research Center Looks to License Malaria Vaccine to Mega Pharma
February 27, 2015
- Keio Researcher to Launch Clinical Trial on Repositioned AD Treatment in April
February 9, 2015
- Yamagata Univ. Hospital Introduces Anticancer Agent Dispensing Robot
January 23, 2015
- Nagoya University Concludes Diovan Study Data Trustworthy
December 24, 2014
- AGs Could Hinder Optimization of Healthcare Spending, Reduce Patients’ Options: Prof. Sakamaki
December 24, 2014
- Jikei Concludes Event Data Unnatural in Diovan Study
December 15, 2014
- British Medical Journal Retracts Sub-Analysis Paper of VART Study
December 11, 2014
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…